Salvage chemotherapy using a combination of fludarabine and cyclophosphamide for refractory or relapsing indolent and aggressive non-Hodgkin's lymphomas

Izidore Lossos, Ora Paltiel, Aaron Polliack

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

The prognosis of patients with refractory or relapsing non-Hodgkin's lymphoma (NHL) after primary therapy is poor and multi-drug salvage treatments are associated with less than 60% response rates, usually of short duration. Here we report the results of a phase II study using a fludarabine-cyclophosphamide (FAMP-Cy) combination as a salvage failure regimen in refractory and relapsing low-grade (6) and intermediate-grade (9) NHL patients. Fifteen patients, who had received up to 4 regimens prior to therapy with FAMP-Cy were treated with fludarabine (25 mg/ml2) and cyclophosphamide (300 mg/m2) for 3 consecutive days followed by G-CSF (5 μg/kg). The overall response was 74%, 4 achieving complete responses (CR) and 7 partial responses (PR). All patients with low-grade NHL responded (4 CR, 2 PR); 5 patients with intermediate-grade NHL achieved PR lasting for a median of 5 months. The main toxicity encountered was moderate myelosuppression. Three patients had febrile neutropenia, one had drug-induced fever and a single patient developed severe neurotoxicity. Opportunistic infections due to lymphopenia were not seen. The combination of fludarabine and cyclophosphamide used as a salvage regimen showed an impressive response in a small group of heavily pretreated low-grade NHL patients who had previously received a large number of prior regimens. FAMP-Cy had limited effect in a similar group of intermediate-grade NHL patients. Results with this 'failure' regimen are encouraging, however further studies are needed in order to confirm these observations in a larger series of patients.

Original languageEnglish
Pages (from-to)155-160
Number of pages6
JournalLeukemia and Lymphoma
Volume33
Issue number1-2
StatePublished - Mar 17 1999
Externally publishedYes

Fingerprint

Non-Hodgkin's Lymphoma
Cyclophosphamide
Drug Therapy
fludarabine
Salvage Therapy
Febrile Neutropenia
Lymphopenia
Opportunistic Infections
Granulocyte Colony-Stimulating Factor
Pharmaceutical Preparations
Fever
Therapeutics

Keywords

  • Fludarabine
  • Fludarabine + cyclophosphamide
  • Intermediate grade
  • Low grade
  • Lymphoma
  • Refractory
  • Relapsing lymphoma

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Salvage chemotherapy using a combination of fludarabine and cyclophosphamide for refractory or relapsing indolent and aggressive non-Hodgkin's lymphomas. / Lossos, Izidore; Paltiel, Ora; Polliack, Aaron.

In: Leukemia and Lymphoma, Vol. 33, No. 1-2, 17.03.1999, p. 155-160.

Research output: Contribution to journalArticle

@article{f1db514c0b634a2bbb8eedbd15520203,
title = "Salvage chemotherapy using a combination of fludarabine and cyclophosphamide for refractory or relapsing indolent and aggressive non-Hodgkin's lymphomas",
abstract = "The prognosis of patients with refractory or relapsing non-Hodgkin's lymphoma (NHL) after primary therapy is poor and multi-drug salvage treatments are associated with less than 60{\%} response rates, usually of short duration. Here we report the results of a phase II study using a fludarabine-cyclophosphamide (FAMP-Cy) combination as a salvage failure regimen in refractory and relapsing low-grade (6) and intermediate-grade (9) NHL patients. Fifteen patients, who had received up to 4 regimens prior to therapy with FAMP-Cy were treated with fludarabine (25 mg/ml2) and cyclophosphamide (300 mg/m2) for 3 consecutive days followed by G-CSF (5 μg/kg). The overall response was 74{\%}, 4 achieving complete responses (CR) and 7 partial responses (PR). All patients with low-grade NHL responded (4 CR, 2 PR); 5 patients with intermediate-grade NHL achieved PR lasting for a median of 5 months. The main toxicity encountered was moderate myelosuppression. Three patients had febrile neutropenia, one had drug-induced fever and a single patient developed severe neurotoxicity. Opportunistic infections due to lymphopenia were not seen. The combination of fludarabine and cyclophosphamide used as a salvage regimen showed an impressive response in a small group of heavily pretreated low-grade NHL patients who had previously received a large number of prior regimens. FAMP-Cy had limited effect in a similar group of intermediate-grade NHL patients. Results with this 'failure' regimen are encouraging, however further studies are needed in order to confirm these observations in a larger series of patients.",
keywords = "Fludarabine, Fludarabine + cyclophosphamide, Intermediate grade, Low grade, Lymphoma, Refractory, Relapsing lymphoma",
author = "Izidore Lossos and Ora Paltiel and Aaron Polliack",
year = "1999",
month = "3",
day = "17",
language = "English",
volume = "33",
pages = "155--160",
journal = "Leukemia and Lymphoma",
issn = "1042-8194",
publisher = "Informa Healthcare",
number = "1-2",

}

TY - JOUR

T1 - Salvage chemotherapy using a combination of fludarabine and cyclophosphamide for refractory or relapsing indolent and aggressive non-Hodgkin's lymphomas

AU - Lossos, Izidore

AU - Paltiel, Ora

AU - Polliack, Aaron

PY - 1999/3/17

Y1 - 1999/3/17

N2 - The prognosis of patients with refractory or relapsing non-Hodgkin's lymphoma (NHL) after primary therapy is poor and multi-drug salvage treatments are associated with less than 60% response rates, usually of short duration. Here we report the results of a phase II study using a fludarabine-cyclophosphamide (FAMP-Cy) combination as a salvage failure regimen in refractory and relapsing low-grade (6) and intermediate-grade (9) NHL patients. Fifteen patients, who had received up to 4 regimens prior to therapy with FAMP-Cy were treated with fludarabine (25 mg/ml2) and cyclophosphamide (300 mg/m2) for 3 consecutive days followed by G-CSF (5 μg/kg). The overall response was 74%, 4 achieving complete responses (CR) and 7 partial responses (PR). All patients with low-grade NHL responded (4 CR, 2 PR); 5 patients with intermediate-grade NHL achieved PR lasting for a median of 5 months. The main toxicity encountered was moderate myelosuppression. Three patients had febrile neutropenia, one had drug-induced fever and a single patient developed severe neurotoxicity. Opportunistic infections due to lymphopenia were not seen. The combination of fludarabine and cyclophosphamide used as a salvage regimen showed an impressive response in a small group of heavily pretreated low-grade NHL patients who had previously received a large number of prior regimens. FAMP-Cy had limited effect in a similar group of intermediate-grade NHL patients. Results with this 'failure' regimen are encouraging, however further studies are needed in order to confirm these observations in a larger series of patients.

AB - The prognosis of patients with refractory or relapsing non-Hodgkin's lymphoma (NHL) after primary therapy is poor and multi-drug salvage treatments are associated with less than 60% response rates, usually of short duration. Here we report the results of a phase II study using a fludarabine-cyclophosphamide (FAMP-Cy) combination as a salvage failure regimen in refractory and relapsing low-grade (6) and intermediate-grade (9) NHL patients. Fifteen patients, who had received up to 4 regimens prior to therapy with FAMP-Cy were treated with fludarabine (25 mg/ml2) and cyclophosphamide (300 mg/m2) for 3 consecutive days followed by G-CSF (5 μg/kg). The overall response was 74%, 4 achieving complete responses (CR) and 7 partial responses (PR). All patients with low-grade NHL responded (4 CR, 2 PR); 5 patients with intermediate-grade NHL achieved PR lasting for a median of 5 months. The main toxicity encountered was moderate myelosuppression. Three patients had febrile neutropenia, one had drug-induced fever and a single patient developed severe neurotoxicity. Opportunistic infections due to lymphopenia were not seen. The combination of fludarabine and cyclophosphamide used as a salvage regimen showed an impressive response in a small group of heavily pretreated low-grade NHL patients who had previously received a large number of prior regimens. FAMP-Cy had limited effect in a similar group of intermediate-grade NHL patients. Results with this 'failure' regimen are encouraging, however further studies are needed in order to confirm these observations in a larger series of patients.

KW - Fludarabine

KW - Fludarabine + cyclophosphamide

KW - Intermediate grade

KW - Low grade

KW - Lymphoma

KW - Refractory

KW - Relapsing lymphoma

UR - http://www.scopus.com/inward/record.url?scp=0033011668&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033011668&partnerID=8YFLogxK

M3 - Article

VL - 33

SP - 155

EP - 160

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

SN - 1042-8194

IS - 1-2

ER -